Search Results
Jan 28, 2026, 07:00 ET Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced
More news about: Samsung Biologics
Jan 28, 2026, 03:11 ET Společnost Skyhawk Therapeutics oznamuje průběžné výsledky za devět měsíců u pacientů z 1. fáze klinického hodnocení přípravku SKY-0515 pro léčbu Huntingtonovy choroby
Léčba přípravkem SKY-0515 vede v závislosti na dávce ke snížení obsahu proteinu mHTT v krvi o 62 % a k redukci mRNA PMS1 o 26 % při dávce 9 mg. PMS1 je klíčovým faktorem expanze somatických CAG repetic a patologie HD. Přípravek SKY-0515 rovněž prokázal vynikající
More news about: Skyhawk Therapeutics
Jan 27, 2026, 22:10 ET Spoločnosť Skyhawk Therapeutics oznamuje predbežné výsledky u pacientov z fázy 1 klinického skúšania lieku SKY-0515 za deväť mesiacov liečby Huntingtonovej choroby
Liečba liekom SKY-0515 vedie k dávkovo závislému zníženiu hladiny proteínu mHTT v krvi o 62 % pri dávke 9 mg a k dávkovo závislému zníženiu hladiny mRNA proteínu PMS1 o 26 %. Proteín PMS1 je kľúčovým faktorom expanzie opakovaní somatického CAG a patológie HD. Liek SKY-0515 tiež preukázal vynikajúci vplyv
More news about: Skyhawk Therapeutics
Jan 27, 2026, 10:50 ET Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
include:Moderna (NASDAQ: MRNA) and Merck (NYSE: MRK) announced median five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, demonstrating
More news about: Equity Insider
Jan 27, 2026, 10:22 ET Skyhawk Therapeutics Công Bố Kết Quả Nghiên Cứu Tạm Thời trên Bệnh Nhân sau 9 Tháng tiến hành Thử Nghiệm Lâm Sàng Giai Đoạn 1 thuốc SKY-0515 để Điều Trị bệnh Huntington
Việc điều trị bằng SKY-0515 làm giảm 62% lượng protein mHTT trong máu với liều 9mg (phụ thuộc liều) và giảm 26% lượng mRNA PMS1 (phụ thuộc liều). PMS1 là yếu tố then chốt thúc đẩy sự mở rộng lặp đoạn CAG trong tế bào soma và sự tiến triển bệnh lý của HD. SKY-0515 cũng đã
More news about: Skyhawk Therapeutics
Jan 27, 2026, 09:40 ET Skyhawk Therapeutics ogłasza dziewięciomiesięczne wyniki pośrednie badań klinicznych fazy 1 nad lekiem SKY-0515 stosowanym w leczeniu choroby Huntingtona
pomocą SKY-0515 powoduje zależne od dawki zmniejszenie stężenia białka mHTT we krwi o 62% przy dawce 9 mg oraz zależne od dawki zmniejszenie stężenia mRNA PMS1 o 26%. PMS1 jest kluczowym czynnikiem powodującym somatyczną ekspansję powtórzeń CAG i patologię HD. Lek SKY-0515 wykazał również doskonałą ekspozycję
More news about: Skyhawk Therapeutics
Jan 27, 2026, 08:00 ET Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Treatment with SKY-0515 results in dose-dependent reductions of mHTT protein in blood of 62% at the 9mg dose, and dose-dependent PMS1 mRNA reduction of 26%. PMS1 is a key driver of somatic CAG repeat expansion and HD pathology. SKY-0515 has also demonstrated excellent central nervous system
More news about: Skyhawk Therapeutics
Jan 27, 2026, 08:00 ET Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Treatment with SKY-0515 results in dose-dependent reductions of mHTT protein in blood of 62% at the 9mg dose, and dose-dependent PMS1 mRNA reduction of 26%. PMS1 is a key driver of somatic CAG repeat expansion and HD pathology. SKY-0515 has also demonstrated excellent central nervous system
More news about: Skyhawk Therapeutics
Jan 27, 2026, 08:00 ET 스카이호크 테라퓨틱스, 헌팅턴병 치료제 SKY-0515 제1상 임상시험 환자 대상 9개월 중간 결과 발표
용량 수준의 SKY-0515와 위약을 84일간 투여하는 이중눈가림, 위약 대조, 병렬 설계 시험으로, 모든 참가자는 12개월의 활성 투여 연장 기간 동안 눈가림 방식으로 저용량 또는 고용량의 SKY-0515를 투여받는다. 시험 목적에는 변이 HTT 단백질 및 PMS1 mRNA 평가가 포함된다. SKY-0515 파트 C의 첫 환자 투약은 2025년 1월에 시작됐으며, 현재 제1C상 단계의 등록이 완료됐다.SKY-0515 제2/3상 FALCON-HD 임상시험 소개FALCON-HD(
More news about: Skyhawk Therapeutics
Jan 22, 2026, 08:00 ET The Brain Aneurysm Foundation Highlights Recent Advances from its Research Grantees
followed by support from organizations including the Canadian Heart and Stroke Foundation, helped validate an approach to develop lipid nanoparticle mRNA (LNP-mRNA) medicines for a range of CNS disorders. Along with colleagues at the University of British Columbia, Dr. Bernier spun off CereCura Nanotherapeutics
More news about: Brain Aneurysm Foundation
Jan 21, 2026, 02:20 ET Samsung Biologics reports fourth quarter and fiscal year 2025 financial results
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced
More news about: Samsung Biologics
Jan 15, 2026, 16:06 ET Disrupting Biotech: Jurek Kozyra Unveils DNA Nanorobots That Could Cure the Incurable
"If you can target mRNA very specifically, that means that in theory, you could potentially cure all diseases," says Kozyra. "That's why this area is so exciting right now."The
More news about: Disruption Interruption
Jan 15, 2026, 08:30 ET Emerging LNP Technology and mRNA Strategies for In Vivo CAR-T Development, Upcoming Webinar Hosted by Xtalks
principles of mRNA and LNP technology and their unique advantages for in vivo CAR T-cell development. Attendees will learn how mRNA synthesis, LNP formulation and analytical testing support platform optimization. The featured speaker will share the latest advancements in mRNA and LNP-based
More news about: Xtalks
Jan 14, 2026, 08:23 ET Cereno Scientific Announces First Peer-Reviewed Publication on HDAC Inhibitor CS014: Antithrombotic Efficacy Without Bleeding Risk Supports Broad Potential in Cardiopulmonary Diseases
while preserving the mechanistic benefits of HDAC inhibition. The work shows that CS014 maintains efficacious HDAC inhibitory activity, increases tPA mRNA expression and produces strong antithrombotic effects in small artery, large artery and large vein models. Notably, CS014 achieves these effects while
More news about: Cereno Scientific
Jan 14, 2026, 08:13 ET Cereno Scientific Announces First Peer-Reviewed Publication on HDAC Inhibitor CS014: Antithrombotic Efficacy Without Bleeding Risk Supports Broad Potential in Cardiopulmonary Diseases
while preserving the mechanistic benefits of HDAC inhibition. The work shows that CS014 maintains efficacious HDAC inhibitory activity, increases tPA mRNA expression and produces strong antithrombotic effects in small artery, large artery and large vein models. Notably, CS014 achieves these effects while
More news about: Cereno Scientific
Jan 14, 2026, 08:00 ET From Path to Progress: Journal of Independent Medicine Launches 2026 With Its Fifth Issue--Entering Year Two of Conflict-Free, Evidence-Based Science
(2026)RNA:DNA Hybrids Survive Digestion in mRNA Vaccine Manufacturing — Kevin McKernan; Charles Rixey; Jessica RoseFinds evidence of residual DNA-related impurities—particularly RNA:DNA hybrids—in tested mRNA vaccine lots and argues current dsDNA-only quantification
More news about: Independent Medical Alliance
Jan 13, 2026, 20:22 ET 管線成果超預期，獲數千萬港幣里程碑付款！晶泰科技賦能AI+RNA新藥RTX-117獲中美臨床批件
患者群體，還具備極大的適應症拓展潛力，潛在覆蓋人群預估超過 5000 萬，是現有 CMT 患者數量的近 20 倍。RTX-117 的作用機制在於精準靶向 CMT 致病的關鍵通路，通過抑制異常激活的整合應激反應（Integrated Stress Response, ISR），恢復 mRNA 的正常翻譯，從而發揮療效。據 ReviR 消息，臨床前數據顯示，RTX-117 展現出高藥效強度和高水平的靶點結合能力，對 ISR 抑制效果顯著，並能有效恢復模型動物的運動能力。RTX-117 為晶泰科技與 ReviR 深度合作的一系列研發管線中首個里程碑成果，其臨床前數據及臨床獲批速度均超出雙方預期。即將開展的臨床研究將評估該突破性療法的安全性和有效性，為全球數百萬受
More news about: 晶泰科技
Jan 13, 2026, 07:30 ET Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
designed using Ractigen's proprietary SCAD™ delivery platform technology to specifically target and silence the superoxide dismutase 1 (SOD1) gene mRNA. Mutations in the SOD1 gene cause a toxic gain-of-function and are a known cause of familial ALS. By reducing the production of the toxic mutant SOD1
More news about: Ractigen Therapeutics
Jan 09, 2026, 07:00 ET Nona Biosciences Enters into Collaboration Agreement with Link Cell Therapies to Advance CAR-T Cell Therapies
antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.By integrating Harbour Mice®, single-B cell screening technology, NonaCarFx™ (a direct CAR-function-based
More news about: Nona Biosciences
Jan 08, 2026, 16:00 ET CREATE Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
Francisco, CAAbout CREATE MedicinesCREATE Medicines is a clinical-stage biotech pioneering in vivo CAR therapy. Its proprietary mRNA-LNP platform directly programs immune cells inside the body to deliver scalable, repeat-dose, off-the-shelf immunotherapies. With proven human validation,
More news about: CREATE Medicines, Inc.
Jan 08, 2026, 11:39 ET Bionova Scientific and Syenex Forge Strategic Alliance to Expand Access to High-Quality Plasmid DNA for Advanced Therapies
the platform delivers robust, reproducible plasmids suitable for use in all genetic medicine formats, including LVV production or for mRNA manufacturing as DNA templates.Under the agreement, Bionova will serve as the preferred manufacturing partner for Syenex's best-in-class
More news about: Bionova Scientific
Jan 08, 2026, 08:38 ET Mercury Bio Launches MB-TIP™--Revolutionizing Immunotherapy with Intracellular Targeting
with direct uptake into neurons. These same preclinical models also confirmed the delivery of significant therapeutic amounts of proteins and mRNA into neuronal cytoplasm, without endosomal degradation. "The biggest obstacle to creating a disease‑modifying therapy for neurological diseases
More news about: Mercury Bio Inc.
Jan 08, 2026, 07:00 ET Replicate Bioscience Awarded Grants to Develop New srRNA Vaccines for HIV and Malaria
existing mRNA approaches, with potential improvements in bioactivity, induction of more potent immune responses, and improved therapeutic index. RBI-4000, the company's clinical-stage srRNA rabies vaccine, has demonstrated protective levels of immunity at doses lower than any other reported mRNA or srRNA
More news about: Replicate Bioscience
Jan 07, 2026, 14:29 ET Virbac Launches URSOLYX™ Soft Chews for Cats: Feline Muscle Support Supplement
Unlike conventional joint supplements, URSOLYX™ Soft Chews for Cats feature ursolic acid, a natural compound that works at the molecular level to inhibit mRNA expression changes associated with muscle atrophy, maintaining functional muscle health."With URSOLYX™ Soft Chews, we're empowering cat owners
More news about: Virbac
Jan 07, 2026, 10:30 ET Pharmaceutical Microfiltration Market worth $9.94 billion by 2030 | MarketsandMarkets™
therapeutic trends. A major driving force behind this shift is the increasing production of biologics, biosimilars, and advanced therapies, such as mRNA vaccines and cell & gene therapies. This surge in production is creating a higher demand for high-performance consumables, including depth filters,
More news about: MarketsandMarkets